Lexaria Bioscience (LEXX) provided progress updates on its Phase 1b, 12-week chronic study GLP-1-H24-4 underway in Australia. Lexaria has ...
Q1 2025 Management View CEO Robert Mauch highlighted strong Q1 performance with 13% revenue growth and a 14% increase in adjusted EPS. He attributed this success to robust execution in the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback